Biocept Inc

Biocept brings tremendous value to the healthcare system with its AI partnership

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive Investors the California-based molecular diagnostics company is making progress on its artificial intelligence collaboration with Prognos Inc.

Nall says Prognos uses data that Biocept generates with its liquid biopsy tests from different cancers to analyze trends to identify and develop targeted therapies based on the genomic of a patient's tumor. Nall says investors should look out for how Biocept and Prognos sell this data to Big Pharma and create an additional revenue stream.

Quick facts: Biocept Inc

Price: $0.96

Market: NASDAQ
Market Cap: $22.1 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Full interview: Biocept unveils revenue lift in 2Q earnings, bolsters IP...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive the liquid biopsy provider reported a 45% boost in revenue during the second quarter of 2019, compared with the same period a year ago, driven largely by an increase in its commercial samples. What's more, Nall says, the California-based...

1 week, 3 days ago

2 min read